title: [Benzodiazepin addiction: a silent addiction among older people].
abstract: Benzodiazepines are frequently prescribed for a longer period of time for anxiety disorders and insomnia in spite of the many guidelines to prescribe these drugs only short-term. These guidelines are based on the risk-benefit balance between long-term effectiveness and side effects like addiction, anterograde amnesia, and increased risk on falling (resulting in hip fractures), traffic accidents and even mortality. Also low-dose benzodiazepine use can lead to benzodiazepine dependence. Although initially most attention has been paid to the physical withdrawal syndrome, psychological aspects of benzodiazepine dependence have received more and more attention in the past decades. Recently, a relationship between the brain-reward system, involved in addiction, and benzodiazepine use, was demonstrated. When long-term benzodiazepine use is recognised as problematic by both physician and patient, different treatment modalities are available to support patients in achieving abstinence. One of every four patients is able to stop by themselves with the aid of a minimal intervention providing psychoeducation and encouragement. Two out of three long-term uses are able to stop their usage with the aid of systematic tapering protocols guided by a physician or psychologist. In case of an underlying insomnia or anxiety disorder, cognitive-behavioural therapy should be added to the tapering protocol. In contrast to the general opinion, advanced old age has no negative impact on the treatment response.
authors: UMC Groningen. r.c.oude.voshaar@umcg.nl
authors: R C
authors: RC
authors: Oude Voshaar
mesh_terms: D000368:Aged; D000375:Aging / Q000523:psychology*; D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D018570:Risk Assessment; D019966:Substance-Related Disorders / Q000453:epidemiology / Q000209:etiology*
chemical_list: D014151:Anti-Anxiety Agents; D001569:Benzodiazepines